1 TG Dekker – WHO, MalaysiaFeb 2005
PharmaceuticalResearch and Development
Considerations
Workshop on GMP and Quality Assurance of
Multisource Tuberculosis MedicinesKuala Lumpur – Malaysia
21-25 February 2005
Theo Dekker, D.Sc., consultant to WHOResearch Institute for Industrial Pharmacy
North-West University, Potchefstroom, South [email protected]
2 TG Dekker – WHO, MalaysiaFeb 2005
Abbreviations
API Active pharmaceutical ingredientBCS Biopharmaceutics classification systemBP British PharmacopoeiaCEP EU certificate of suitabilityEOI Expression of interestFDC Fixed dose combinationFPP Finished pharmaceutical productICH International Conference on HarmonizationInt.Ph. International PharmacopoeiaR&D Research and developmentTB TuberculosisXRPD X-ray powder diffractogramUSP United States Pharmacopeia
3 TG Dekker – WHO, MalaysiaFeb 2005
The perspective
Pharmaceutical R & D provides the foundation of the activities aimed at ensuring that the patient receives an FPP (product) that consistently meets established standards & specifications of Safety Efficacy Quality
The FPP should be stable - and thus retain these standards – throughout the shelf-life, if kept in the original packaging when correctly distributed, stored & handled
4 TG Dekker – WHO, MalaysiaFeb 2005
Pharmaceutical R&D
1. Learn about the product through desk research: Don’t try to reinvent the wheel Collect & analyse available information on e.g. APIs,
formulas, excipients, compatibility, stability, dosage form, strength, packaging & analysis
Compile a Product Profile Report
2. Development according to plan, including: Preformulation studies Formula / dosage form development & packaging Comparative dissolution against comparator FPP Accelerated stability Final formula / manufacturing process
5 TG Dekker – WHO, MalaysiaFeb 2005
Topics for discussion
1. Desk research – Product Profile Report
2. The FDCs anti-tuberculosis tablets – a problem mix API-API interactions of particular importance
3. Solid state properties of APIs Rifampicin as example
4. Biowaiver type of comparative dissolutions Formulation development & comparison of pivotal
batches Setting product dissolution specifications Pre-BE control Post-approval changes
6 TG Dekker – WHO, MalaysiaFeb 2005
Product profile report
Objective To compile a comprehensive summary, with
conclusions, of all available information that may be important for the development of the product
To have a standard (pro-forma) style for the report, facilitating compilation/application
Assign experts in preparation of relevant parts To use this report as base for development
pharmaceutics (though considered part thereof) Example
4FDC anti-tuberculosis tablets
7 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (1)
PRODUCT UNDER CONSIDERATION 4FDC anti-tuberculosis solid oral dosage form
Reference product(s) information1. Category
Anti-tuberculosis agent
2. WHO model list of essential drugs (current) Rifampicin 150 mg, Isoniazid 75 mg, Pyrazin-
amide 400 mg & Ethambutol 2HCl 275 mg
3. Prequalification EOI requirement (current) As for WHO model list – as tablets
8 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (2)
4. Prequalified products according to current list Wyeth Pakistan - tablet (blister) Lupin India – tablet (blister, HDPE bottle) Sandoz – tablet (blister)
5. Public assessment reports available None (FDA, EPAR, WHOPAR)
6. Comparator product (bio-section) Sandoz (registered in Sweden)? Clarify Combination of loose tablets? Clarify
7. Other products with “marketing authorisation” List such products, where considered necessary
9 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (3)
8. Products available for inspection/testing Wyeth Pak, Lupin, Sandoz, others Comparator for comparing dissolution profiles
9. Description/appearance of reference products Especially the prequalified products (i.a. for
patient compliance) Product A: Red oblong film-coated tablets, etc.
10.Packaging / pack sizes Prequalified products important (see website) HDPE bottles (100s?), 3 x 10 blisters (alu/alu?)?
10 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (4)
11.Storage requirements /shelf life Especially the prequalified 4FDC tablets From SmPC or PIL
12.Published product specific excipients Tabulate for all prequalified/registered products
where available (table for comparative purposes) Public assessment reports (not available for the
4FDC tablets) From SmPCs (also available on internet) Document known incompatibilities with APIs
11 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (5)
13.Published formulas Formulas are published for older products in
standard works and journals (see next page)
14.Official product monographs USP 28 (always current) for 4FDC 2 HPLC assay methods for all four APIs Dissolution test for all four APIs Related substances (degradants) not included
15.Safety & efficacy information Requirements for BE studies Comparator product(s)
12 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (6)
Typical books for formulation and excipients: S. K. Niazi. Handbook of Pharmaceutical Manufacturing
Formulations. CRC Press, Boca Raton (current edition): Volume 1. Compressed Solid Products Volume 2. Uncompressed Solid Products Volume 3. Liquid Products Volume 4. Semisolid Products Volume 6. Sterile Products
Handbook of Pharmaceutical Excipients. A.H. Kibbe, ed. 3rd edition. American Pharmaceutical Association, Washington, 2000 (Pharmaceutical Press, London)
13 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (7)
API information16.Nomenclature
INN, USAN, Systematic name , CAS, etc. from e.g. Merck Index for each API (standard)
17.General physical properties Discuss/tabulate properties of each API in terms of
the guidance for dossier requirements, with special attention to unique API properties, e.g.
Rifampicin (pseudo) polymorphism and dissolution Hygroscopicity of ethambutol 2HCl Comparison of solubilities (analytically important)
14 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (8)
18.Compedial monograph(s) BP/Ph.Eur., Int.Ph. and USP for all 4 APIs
19.Stability & degradation routes Compile expert report for each of the 4 APIs Stress data and mild conditions from literature in:
- solution and solid state API/API and API/excipient interactions Storage conditions and optimal analytical stability Conclusions and precautions with respect to
intended product
15 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (9)
20.Possible BCS classification Biowaivers (in vitro dissolution instead of
bioequivalence studies) for immediate release solid orals (tablets, capsules) are not in current prequalification guidelines. Biowaivers used for demonstration of equivalence of lower vs higher strength in proportional similar formulations.
FDA and EMEA guidelines exist for classification “rules”, dissolution requirements and similarity of profiles
16 TG Dekker – WHO, MalaysiaFeb 2005
Typical product profile report (10)
Recommendations File hard copies of all sources in support of the
Product Profile Report The data in the Product Profile Report can be
used inter alia: To form the basis of development pharmaceutics
& to identify further experimental investigations To alert the development team of possible
problems To identify monograph & analytical shortcomings
17 TG Dekker – WHO, MalaysiaFeb 2005
4FDC tablets – a problem mix (1)
Composition in current Essential Drug List
Rifampicin 150 mg Isoniazid 75 mg Pyrazinamide 400 mg Ethambutol 2HCl 275 mg Total API weight 900 mg Typical tablet weight ~ 1.3 g
18 TG Dekker – WHO, MalaysiaFeb 2005
4FDC tablets – a problem mix (2)
Rifampicin Oxidation (quinone & N-oxide)
Protect from air exposure Hydrolysis (3-formylrifamycin & 25-desacetyl)
Wet granulation / drying a potential problem? Reaction with Isoniazid
3-(isonicotinylhydrazinomethyl)rifamycin or more commonly known as isonicotinyl hydrazone
isonicotinyl hydrazone major decomposition product Light sensitive
Product to be protected from light exposure
19 TG Dekker – WHO, MalaysiaFeb 2005
4FDC tablets – a problem mix (3)
hydrolysis Rifampicin
oxidation hydrolysis
20 TG Dekker – WHO, MalaysiaFeb 2005
4FDC tablets – a problem mix (4)
Isoniazid Reacts with aldehydes/reducing sugars
Sugar & lactose to be avoided in formulation !! 3-Formylrifamycin (from rifampicin)
Ethambutol hydrochloride (2HCl) Hygroscopic
Absorbs water for reaction in tablets Creates slightly acidic conditions
pH of 2% w/v solution: 3.7-4.0 (BP) The acidic conditions enhance rifampicin/isoniazid reaction
(isonicotinyl hydrazone formation)
21 TG Dekker – WHO, MalaysiaFeb 2005
4FDC tablets – a problem mix (5)
Isonicotinyl hydrazone (3-(isonicotinylhydrazinomethyl)rifamycin) This is major decomposition product in tablets
containing rifampicin and isoniazid Series of articles by dr. S. Singh et al. (NIPER), e.g.
S. Singh, T. T. Mariappan, N. Sharda, S. Kumar & A. K. Chakraborti. The reason for an increase in decomposition of rifampicin in the presence of isoniazid under acid conditions. Pharm. Pharmacol. Commun., 6, 405-410 (2000)
The reactions shown on next slide are from the above publication
23 TG Dekker – WHO, MalaysiaFeb 2005
4FDC-TB tablets exposed to 40°C/75%RH for one week
Two products. “Bleeding” may start after more exposure (in-house)
Control on left Control on left
24 TG Dekker – WHO, MalaysiaFeb 2005
4FDC-TB tabletspreventative/protective measures
Formulation - no sugar/lactose (isoniazid) Separate granulation of rifampicin & isoniazid Rifampicin as powder (not granulate)?
Prevent oxidation & hydrolysis Low water content of tablet (USP ≤ 3.0%) Protect product from moisture and oxygen
Non-permeable packaging Do not remove from primary packaging Avoid repackaging
Light protection Differential formulation, e.g. delayed release &
immediate release in one tablet ??
25 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin solid state properties
Rifampicin exist is 3 solid state forms: Polymorph I Polymorph II Amorphous form
Commercial material contains: Polymorph II (predominantly) Mixture of polymorph II and amorphous form
Five commercial samples (A to E) in examples:Sample A: Form II Sample B: Form IISample C: Form II + amorphSample D: Form II + amorphSample E: Form II
26 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin - SEM photos
Sample A Sample DForm II Form II +
amorph
27 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin -XRPDs
Top: Sample A (Form II – sharp signals)Middle: Sample C (Form II + amorph – intensity drop)Bottom: Amorphous form (no pattern)
28 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin – powder dissolution (1)
Medium: 0.1 M hydrochloric acid
Profiles of all samples are similar Dissolves immediately in 0.1 M hydrochloric acid
29 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin – powder dissolution (2)
Medium: Phosphate buffer pH 7.4
Profiles A, B & E are similar (f2 ≥ 50) Profiles C & D are similar (f2 ≥ 50) - dissolution incomplete Profiles A, B, E dissimilar from profiles C,D (f2 < 50)
A, B, E(form II)
C, DForm II + Amorph
30 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin – powder dissolution (3)
Medium: Water
Profiles A, B & E are similar (f2 ≥ 50) Profiles C & D are similar (f2 ≥ 50) - dissolution incomplete Profiles A, B, E dissimilar from profiles C,D (f2 < 50)
A, B, E(form II)
C, D(form II + amorph)
31 TG Dekker – WHO, MalaysiaFeb 2005
Rifampicin - solid state conclusions
1. Solid state forms identifiable by means of XRPD2. Dissolution rate is not different in 0.1 M HCl3. Presence of amorphous form slows down dissolution
at higher pH (f2 test) Incomplete dissolution after 65 minutes !! May fail USP tolerance at pH 6.8 (75% in 45 min.) ?? Agglomeration / wettability?
4. Comparative powder dissolution powerful tool for supplier selection
Reference: S. Q. Henwood, M. M. de Villiers, W. Liebenberg, A.P.
Lötter. Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev. & Ind. Pharm. 26, 403-408 (2000) (Research Institute for Industrial Pharm.)
32 TG Dekker – WHO, MalaysiaFeb 2005
Polymorphism – important situations
When it has a significant effect on the rate of dissolution of the API in water and biological fluid, that may affect the absorption of the API Of special importance for practically insoluble
APIs When it can affect the manufacturing process, e.g. in
the case of flow properties Where the properties differs to such extent that
different forms can be used in different dosage forms (nevirapine: anhydrate in tablets and the hemihydrate in suspensions)
33 TG Dekker – WHO, MalaysiaFeb 2005
BCS classification (1)
High solubility: Highest dose strength of API should be soluble in ≤ 250 ml water at 37ºC over the pH range 1.0-7.5.
High permeability: Absolute bioavailability ≥ 90 % (presently) - apart from specific permeability studies
Limiting factors for biowaivers (see FDA & EMEA)
Class Solubility Permeability
1 High High
2 Low High
3 High Low
4 Low Low
34 TG Dekker – WHO, MalaysiaFeb 2005
BCS classification (2)
Data from: M Lindenberg, S. Kopp, J. B. Dressman.
Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.Eur. J. Pharm. Biopharm., 58, 265-278 (2004)
None of other TBs (mainly for injection, thus not classified) in 5th inv. for EOI in publication – a number of ARVs are
API (INN) Class
Rifampicin 2 (tentative)
Isoniazid 1 (tentative)
Pyrazinamide 1
Ethambutol 2HCl 3 (tentative)
35 TG Dekker – WHO, MalaysiaFeb 2005
Biowaiver dissolution studies (1)
Conditions1. Three media - 900 ml or less - all at 37°C
1. Buffer pH 1.2, SGF without enzymes or 0.1M HCl 2. Buffer pH 4.5 3: Buffer pH 6.8 or SIF without enzymes
Water may be used additionally (not instead of)2. Paddle at 50 or basket at 100 rpm3. Twelve units of each product in all 3 media4. Dissolution samples collected at short intervals, e.g.
10, 15, 20, 30, 45 and 60 minutes Analyse samples for all APIs
36 TG Dekker – WHO, MalaysiaFeb 2005
Biowaiver dissolution studies (2)
Evaluation of dissolution data1. The profiles of the test and reference products
must be similar in all three media for considering a biowaiver (for not doing BE)
2. The profiles of the two products in a particular medium is considered similar: If the similarity factor f2 ≥ 50 (see FDA/EMEA for calc) Not all values can be considered for calculation of f2 (see
EMEA guideline) – only one point beyond 85% dissolution, for both APIs (point zero also excluded)
If both products show ≥ 85% dissolution in 15 minutes
37 TG Dekker – WHO, MalaysiaFeb 2005
Biowaiver type dissolution application
1. Important during development studies Formulation selection. Comparison of different lab /
development batches with innovator product. Important for comparison of pivotal batches to
demonstrate in vitro similarity Aids in selecting FPP dissolution conditions/specification
2. Bioequivalence support Ideal pre-bioequivalence control - profile similarity with
comparator product good indication of BE Biowaiver studies not in current prequalification
guidelines.
3. Post-approval changes
38 TG Dekker – WHO, MalaysiaFeb 2005
Comparative dissolution example
Example Ethambutol hydrochloride/Isoniazid 400/150 mg
Tablets Four manufacturers (A, B, C & D) Dissolution conditions:
Paddle, 50 rpm Phosphate buffer pH 6.8, 500 ml, undegassed, 37ºC Pull times: 10, 15, 20, 30, 45 & 60 minutes
Source: T.G. Dekker, E.Swanepoel, A-M Redelinghuys & E.C. van Tonder - unpublished
39 TG Dekker – WHO, MalaysiaFeb 2005
Ethambutol 2HCl & Isoniazid Tabs (1)
Product B
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
Withdrawal time in minutes
Dis
solu
tio
n (
%)
Ethambutol HCl
Isoniazid
Product A
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
Withdrawal time in minutes
Dis
solu
tio
n (
%)
Ethambutol HCl
Isoniazid
40 TG Dekker – WHO, MalaysiaFeb 2005
Ethambutol 2HCl & Isoniazid Tabs (2)
Product C
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
Withdrawal time in minutes
Dis
solu
tio
n (
%)
Ethambutol HCl
Isoniazid
Product D
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
Withdrawal time in minutes
Dis
solu
tio
n (
%)
Ethambutol HCl
Isoniazid
41 TG Dekker – WHO, MalaysiaFeb 2005
Ethambutol 2HCl & Isoniazid Tabs (3)
All 4 productsAPI: Isoniazid
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
Withdrawal time in minutes
Dis
solu
tio
n (
%)
All 4 productsAPI: Ethambutol
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70
Withdrawal time in minutes
Dis
solu
tio
n (
%)
A
B,C
D
42 TG Dekker – WHO, MalaysiaFeb 2005
Ethambutol 2HCl & Isoniazid Tabs (4)
Evaluation of dissolution data The dissolution profiles of the APIs in a particular
product are similar (this holds for all 4 products) Both APIs are highly soluble (BCS definition)
The products show different dissolution rates Dissolution rate A > B ≈ C >> D Disintegration (min) 7 11 11 21 Dissolution rate related to disintegration time f2 values show that B & C have similar profiles Dissolution method discriminating
Typical type of results during pharmaceutical R&D
43 TG Dekker – WHO, MalaysiaFeb 2005
Some conclusions1. Get to know you product through systematic desk
research, e.g. Product Profile Report2. Physical properties of APIs may be important for low
soluble APIs, e.g. polymorphism & particle size Powder dissolution testing may be useful for sourcing
3. Consider important API properties and API-API interactions, especially in FDCs in formulation Packaging to be non-permeable and light protective
4. Biowaiver type dissolutions are important in: Choice of formulation vs comparator Comparison of pivotal batches Setting product dissolution specifications Pre-BE control Post-approval changes